Mind Medicine (MindMed) Inc.
MMED.NE
CBOE CA14.90
CAD
+1.29
- -
Mind Medicine (MindMed) Inc.
MMED.NE
(CBOE CA)
Recent
price
14.90
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Mind Medicine (MindMed) Inc. is a clinical-stage pharmaceutical company focused on developing psychedelic-inspired medicines and therapies to address mental health and addiction disorders. The company manufactures and develops proprietary drugs and treatments including psychoplastogens, psychedelic pharmaceutical compounds such as LSD and MDMA analogs, and novel formulations intended for neuropsychiatric applications. MindMed's product and service portfolio includes drug development programs targeting anxiety, depression, ADHD, PTSD, and substance use disorders, leveraging both synthetic psychedelics and digital therapeutics platforms. Founded in 2019, MindMed operates primarily in North America with research and development facilities headquartered in New York City, USA. The company’s recent strategic developments include expanding its clinical trial pipeline and advancing multiple drug candidates through Phase 2 trials. In the past two years, MindMed has enhanced its collaboration network through partnerships with leading neuroscience research institutions and has pursued acquisitions to broaden its drug development capabilities and intellectual property portfolio. Additionally, MindMed has launched new digital therapy programs to complement its pharmaceutical products, reflecting a strategic shift toward integrated, multi-modal mental health solutions. MindMed targets the global neuropsychiatric pharmaceutical market, focusing on patients with unmet medical needs in mood disorders and addiction treatment segments. The company combines pharmaceutical development with technology-driven therapeutic solutions to improve patient outcomes. It continues to expand its footprint through alliances and capital raises to accelerate commercialization plans and international clinical trials. Overall, MindMed is positioned as a leader in the emerging field of psychedelic medicine, with a core emphasis on innovative drug discovery, clinical development, and digital therapy integration. The company remains at the forefront of transforming mental healthcare through novel pharmacological and therapeutic platforms.